Proliferation index and survival in men with prostate cancer starting long-term androgen deprivation therapy in the STAMPEDE clinical trial.

Larissa Mendes,Christopher D Brawley,Emily Grist,Adnan Ali,Sara Santos Vidal,Marina Parry,Sharanpreet Lall,Nafisah B Atako,Sofeya Ishaq,Malissa Richmond,Aine Haran,Alex Hoyle,Leila Zakka,Christopher Sweeney,Noel W. Clarke,Mahesh K. B. Parmar,Nicholas D. James,Louise Brown,Daniel M. Berney,Gerhardt Attard

Proliferation index and survival in men with prostate cancer starting long-term androgen deprivation therapy in the STAMPEDE clinical trial.

2021

5076Background: Treatment intensification with docetaxel or abiraterone improved survival for advanced prostate cancer starting androgen deprivation therapy (ADT) in the Systemic Therapy in Advanci...

Keywords:

treatment intensification
Internal medicine
Systemic therapy
improved survival
Androgen deprivation therapy
Medicine
Docetaxel
Oncology
Clinical trial
Prostate cancer
Proliferation index

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations